Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Cinnarizine
Cat. No.:
OB0225LY-0155
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Cinnarizine is a calcium channel blocker with antihistamine and sedative properties.
Synonym:
Stugeron; Cinarizine; Dimitronal; Stutgin; 298-57-7; 1-Benzhydryl-4-cinnamylpiperazine; 1-Cinnamyl-4-(diphenylmethyl)piperazine; Piperazine, 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-; 1-trans-Cinnamyl-4-diphenylmethylpiperazine; Piperazine, 1-cinnamyl-4-(diphenylmethyl)-
CAS No.:
298-57-7
Compound CID:
1547484
Formula:
C26H28N2
Formula Weight:
368.51
Specification
Relative Density:
1.093 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Cinnarizine can be used in the study of disorders of the vestibular system or play an important role in evaluating its anti-motion sickness effect.
Library Information
Targets:
Histamine receptor; Calcium channel
Receptors:
H1 receptor
Pathways:
Metabolism; Immunology/Inflammation; GPCR/G protein; Membrane transporter/Ion channel; Neuronal signaling
Plate Number:
AOCL-2
Plate Location:
h8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
6.25 mg/mL; 16.96 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
